Damian Eade

Digital

Webinar wrap-up: How pharma can leverage AI-driven synthetic...

Synthetic personas turn static, traditional personas into interactive, evidence-backed simulations.

Digital

Cracking the code: Unlocking key opinion leaders in the digi...

With new guidance, treatment pathways, and medical advances emerging on a regular basis, the pursuit of knowledge and innovation is a never-ending process for healthcare providers.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks